Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Obstructive Sleep Apnea Syndrome in Glaucoma

This study has been terminated.
(recruiting problems)
Sponsor:
Collaborator:
University Hospital, Basel, Switzerland
Information provided by (Responsible Party):
Selim Orguel, University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier:
NCT00313092
First received: April 10, 2006
Last updated: October 1, 2015
Last verified: October 2015

April 10, 2006
October 1, 2015
January 2005
September 2005   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00313092 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Obstructive Sleep Apnea Syndrome in Glaucoma
Does Plasma Matrix-metalloproteinase Activity Predict Glaucomas in Patients With OSAS (Obstructive Sleep Apnea Syndrome) and Does the Level of Plasma Matrix-metalloproteinase Activity Decrease After One Month of nCPAP-treatment
The aim of the study is to determine if plasma matrix-metalloproteinase activity can predict glaucoma in patients with OSAS and if the level of plasma matrix-metalloproteinase activity will decrease after one month of nCPAP-treatment.
Glaucoma is a leading cause of blindness world-wide. Chronic primary open-angle glaucoma is the most common form among Caucasian patients. The key feature of glaucoma is damage to the optic nerve head, which is not necessarily related to an increased intraocular pressure. The prevalence of glaucoma among the patients with sleep apnoea was 7,2%: normal-tension glaucoma 2,9%, primary open-angle glaucoma 4,3%. The prevalence of obstructive sleep apnoea syndrome (OSAS) is around 4-10% for men and 2-4% for women. Matrix metalloproteinases (MMPs) substrates include essentially all extracellular matrix components as well as a wide array of molecules involved in intracellular adhesion, cell-matrix interaction, and cell signalling. However, MMPs effects are not restricted to extracellular matrix degradation. The prevalence of increased MMP in patients with OSAS and its predicting value for an additional glaucoma are not known. Further, we do not know if treatment of OSAS with nasal continuous positive air pressure(nCPAP) can decrease the MMP activity. With this study, we want to determine the prevalence of MMP activity and the prevalence of glaucoma in patients with OSAS. Further, we want to investigate if a nCPAP treatment period of four weeks decreases the MMP activity.
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   None Retained
Description:
plasma
Non-Probability Sample
Patients with sleep apnoe syndrom
  • Obstructive Sleep Apnea Syndrome
  • Glaucoma
Device: nCPAP treatment
treatment with positive air pressure during night
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
60
September 2005
September 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • OSAS planned begin of a nCPAP treatment

Exclusion Criteria:

  • Current malignancy
  • Oral steroids
Both
18 Years to 95 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Switzerland
 
NCT00313092
045-LEJ-2004-002
No
Not Provided
Not Provided
Selim Orguel, University Hospital, Basel, Switzerland
Selim Orguel
University Hospital, Basel, Switzerland
Study Director: Selim Orgül, MD University Eye Clinic Basel
University Hospital, Basel, Switzerland
October 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP